NCT06484829View on ClinicalTrials.gov

Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

March 25, 2024

Primary Completion Date

February 1, 2026

Study Completion Date

April 1, 2026

Conditions
Relapsed or Refractory Multiple Myeloma (RRMM)
Interventions
DRUG

Purinostat Mesylate 4 mg/m2

4 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.

DRUG

Purinostat Mesylate 6 mg/m2

6 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.

DRUG

Purinostat Mesylate 8.4 mg/m2

8.4 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.

Trial Locations (1)

610000

RECRUITING

West China Hospital Sichuan University, Chengdu

All Listed Sponsors
lead

Chengdu Zenitar Biomedical Technology Co., Ltd

INDUSTRY